| Next 10 |
Ad
OTLK News and Press Outlook Therapeutics Inc.
News | Outlook Therapeutics Inc. (NASDAQ:OTLK)
-
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 40,000 ne...
-
2024-12-03 16:52:33 ET More on Outlook Therapeutics Outlook plunges as lead asset fails in wet AMD study Seeking Alpha’s Quant Rating on Outlook Therapeutics Historical earnings data for Outlook Therapeutics Financial information for Outlook Therapeuti...
-
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of...
-
2024-11-29 06:30:01 ET BTIG analyst issues BUY recommendation for OTLK on November 29, 2024 11:02AM ET. The previous analyst recommendation was Buy. OTLK was trading at $1.7591 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
-
2024-11-27 07:21:54 ET More on Outlook Therapeutics Seeking Alpha’s Quant Rating on Outlook Therapeutics Historical earnings data for Outlook Therapeutics Financial information for Outlook Therapeutics Read the full article on Seeking Alpha For...
-
Final efficacy data expected in January 2025 Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the Un...
-
2024-11-08 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for ...
-
2024-10-28 19:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
2024-10-18 07:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stock Information
Get OTLK Alerts
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Website:
Ad
-
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 40,000 ne...
-
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of...
-
2024-11-29 06:30:01 ET BTIG analyst issues BUY recommendation for OTLK on November 29, 2024 11:02AM ET. The previous analyst recommendation was Buy. OTLK was trading at $1.7591 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...